01 8Losec/Prilosec
02 1Zegerid
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2020 Revenue in Millions : 183
2019 Revenue in Millions : 263
Growth (%) : -30
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2021 Revenue in Millions : 180
2020 Revenue in Millions : 183
Growth (%) : -2
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2015 Revenue in Millions : 422
2014 Revenue in Millions : 340
Growth (%) : -19%
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2017 Revenue in Millions : 271
2016 Revenue in Millions : 276
Growth (%) : -2
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2014 Revenue in Millions : -13.20%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2018 Revenue in Millions : 272
2017 Revenue in Millions : 271
Growth (%) : 0%
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2016 Revenue in Millions : 276
2015 Revenue in Millions : 340
Growth (%) : -19
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2019 Revenue in Millions : 263
2018 Revenue in Millions : 272
Growth (%) : -3
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2016 Revenue in Millions : 98
2015 Revenue in Millions : Not Reported
Growth (%) : Not Reported
LOOKING FOR A SUPPLIER?